Our regular round-up of financings in the biotech sector features rounds for TORL BioTherapeutics, Nvelop Therapeutics, D3 Bio, and Century Therapeutics.
Bristol-Myers Squibb chief executive Giovanni Caforio has promised to invest in the company's pipeline at the virtual JP Morgan Healthcare Conference, and demonstrated that commitment by li
Century Therapeutics has emerged from stealth mode to develop a new generation of ‘off the shelf’ cancer cell therapies, with $250 million backing from investors including Bayer.
Disc Medicine has charted a route to market for bitopertin, its drug candidate for rare disease erythropoietic protoporphyria (EPP), after meeting with the FDA.